Merck KGaA, the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases ...

As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease ...

Merck KGaA, the German healthcare and technology group, is in advanced talks to acquire U.S. cancer and rare diseases ...

Merck KGaA is in advanced talks to buy US cancer and rare diseases drugmaker SpringWorks Therapeutics Inc., according to a ...

German healthcare giant Merck KGaA is in advanced talks to acquire U.S.-based Springworks Therapeutics, known for cancer and rare disease treatments. The potential acquisition would enhance Merck's ...

We recently published a list of Jim Cramer Discussed These 12 Stocks Recently. In this article, we are going to take a look ...

It isn’t just artificial intelligence. Chinese biotech companies are now developing drugs faster and cheaper than their US ...

Western drugmakers are striking more deals in China to access “bio-better” treatments for diseases from obesity to cancer, ...

Financial writer advises caution on investing in Merck & Co., Inc. due to negative sentiment and potential price declines. Click for more on MRK Q4 earnings.

Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.

Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates.

As Moderna maps out a more cautious future amid lower-than-expected sales of its current products, the company is bolstering ...